Single answer
Is AgomAb Therapeutics NV American (AGMB) a buy or sell?
4starter turns market data into one clear verdict you can act on.
Create a free account to save tickers and track your signals.
Log in to turn on watchlist alerts.
Decision snapshot
Everything you need to act fast, in one glance.
What is the conclusion?
Right now our advanced algorithms say:
$1 invested is now $1.01 or 0.70%
(In 2 weeks 2 days 21 hours 50 minutes and 48 seconds .)
Do analysts agree?
We compare consensus targets with today's price.
No analyst target data available for this ticker.
Company snapshot
A quick overview of the business and its public profile.
AgomAb Therapeutics NV a clinicalstage biopharmaceutical company develops novel diseasemodifying therapies for immunology and inflammatory diseases with a focus on chronic fibrotic indications with unmet medical needs The companys product pipeline includes Ontunisertib AGMB129 an oral gastrointestinalrestricted small molecule inhibitor of ALK5 or TGFssR1 for the treatment of Fibrostenosing Crohns disease which is in Phase 2a clinical trials and AGMB447 an inhaled small molecule inhibitor of ALK5 or TGFssR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials It also develops AGMB101 a HGFmimetic monoclonal antibody that acts through agonism or stimulation of the MET receptor and has demonstrated antifibrotic and regenerative activity in preclinical models The company was incorporated in 2017 and is headquartered in Antwerp Belgium
Website: https://agomab.com
Rates and inflation backdrop
US inflation for January 2026 was 0.17%. Over the last 12 months, inflation is 2.83%. The 10-year yield is 4.04 and is down -0.110 over the last 30 days.
Inflation sensitivity
We do not have enough data to give you this answer.
Dividend history check
We cannot find any recorded dividends paid in our systems.
Trading liquidity
Yes, the average daily trading liquidity for AgomAb Therapeutics NV American is $5.8M. You should therefore be able to get in and out of your positions relatively fast.
10-year return check
We cannot find data for AgomAb Therapeutics NV American 10 years ago, but if you had invested on 2026-02-06 when the price was $14.65, you would have made a profit of $1.460 per share or 9.97%.
Why this answer
We combine price momentum, volatility, and trend signals to simplify the decision to one word.
Signal engine scans price, trend, and momentum indicators.
Targets and sentiment are checked against the live quote.
We keep the output simple: buy, sell, or hold.
Analyst consensus
How Wall Street targets compare to today's price.
No analyst target data available for this ticker.